104 related articles for article (PubMed ID: 1980338)
1. Receptor-like oncogenes: functional analysis through novel experimental approaches.
Yarden Y
Mol Immunol; 1990 Dec; 27(12):1319-24. PubMed ID: 1980338
[TBL] [Abstract][Full Text] [Related]
2. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene.
Yarden Y; Weinberg RA
Proc Natl Acad Sci U S A; 1989 May; 86(9):3179-83. PubMed ID: 2470093
[TBL] [Abstract][Full Text] [Related]
3. Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy.
Stancovski I; Peles E; Ben Levy R; Lemprecht R; Kelman Z; Goldman-Michael R; Hurwitz E; Bacus S; Sela M; Yarden Y
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):95-103. PubMed ID: 1356018
[TBL] [Abstract][Full Text] [Related]
4. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active.
Yarden Y
Proc Natl Acad Sci U S A; 1990 Apr; 87(7):2569-73. PubMed ID: 1969636
[TBL] [Abstract][Full Text] [Related]
5. The role of the neu oncogene product in cell transformation and normal development.
Kokai Y; Wada T; Myers JN; Brown VI; Dobashi K; Cohen J; Hamuro J; Weiner DB; Greene MI
Princess Takamatsu Symp; 1988; 19():45-57. PubMed ID: 2908355
[TBL] [Abstract][Full Text] [Related]
6. Biochemical analysis of the ligand for the neu oncogenic receptor.
Yarden Y; Peles E
Biochemistry; 1991 Apr; 30(14):3543-50. PubMed ID: 1672825
[TBL] [Abstract][Full Text] [Related]
7. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.
Dougall WC; Qian X; Peterson NC; Miller MJ; Samanta A; Greene MI
Oncogene; 1994 Aug; 9(8):2109-23. PubMed ID: 7913542
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of cellular platelet-derived growth factor receptors induced by an activated neu receptor tyrosine kinase.
Lehtola L; Nistér M; Hölttä E; Westermark B; Alitalo K
Cell Regul; 1991 Aug; 2(8):651-61. PubMed ID: 1685673
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
Ciardiello F; McGeady ML; Kim N; Basolo F; Hynes N; Langton BC; Yokozaki H; Saeki T; Elliott JW; Masui H
Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
[TBL] [Abstract][Full Text] [Related]
10. A 25 kDa polypeptide is the ligand for p185neu and is secreted by activated macrophages.
Tarakhovsky A; Zaichuk T; Prassolov V; Butenko ZA
Oncogene; 1991 Dec; 6(12):2187-96. PubMed ID: 1685016
[TBL] [Abstract][Full Text] [Related]
11. The effects of the normal and oncogenic forms of the neu tyrosine kinase, and the corresponding forms of an immunoglobulin E receptor/neu tyrosine kinase fusion protein, on Xenopus oocyte maturation.
Narasimhan V; Hamill O; Cerione RA
FEBS Lett; 1992 Jun; 303(2-3):164-8. PubMed ID: 1351469
[TBL] [Abstract][Full Text] [Related]
12. Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins.
Wada T; Myers JN; Kokai Y; Brown VI; Hamuro J; LeVea CM; Greene MI
Oncogene; 1990 Apr; 5(4):489-95. PubMed ID: 1970151
[TBL] [Abstract][Full Text] [Related]
13. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract.
Cohen JA; Weiner DB; More KF; Kokai Y; Williams WV; Maguire HC; LiVolsi VA; Greene MI
Oncogene; 1989 Jan; 4(1):81-8. PubMed ID: 2563577
[TBL] [Abstract][Full Text] [Related]
14. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
Weiner DB; Liu J; Cohen JA; Williams WV; Greene MI
Nature; 1989 May; 339(6221):230-1. PubMed ID: 2654648
[TBL] [Abstract][Full Text] [Related]
15. Neu and its ligands: from an oncogene to neural factors.
Peles E; Yarden Y
Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
[TBL] [Abstract][Full Text] [Related]
17. The role of erbB-2 and its ligands in growth control of malignant breast epithelium.
Lupu R; Dickson RB; Lippman ME
Princess Takamatsu Symp; 1991; 22():49-60. PubMed ID: 1688228
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of the early genomic growth factor response in neu oncogene-transformed cells.
Sistonen L; Koskinen PJ; Lehväslaiho H; Lehtola L; Bravo R; Alitalo K
Oncogene; 1990 Jun; 5(6):815-21. PubMed ID: 1972791
[TBL] [Abstract][Full Text] [Related]
19. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
[TBL] [Abstract][Full Text] [Related]
20. ras and neu oncogenes reverse serum inhibition and epidermal growth factor dependence of serum-free mouse embryo cells.
Shirahata S; Rawson C; Loo D; Chang YJ; Barnes D
J Cell Physiol; 1990 Jul; 144(1):69-76. PubMed ID: 1973170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
